Found: 11
Select item for more details and to access through your institution.
Using HScore for Evaluation of Hemophagocytosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children.
- Published in:
- Biomedicines, 2024, v. 12, n. 2, p. 294, doi. 10.3390/biomedicines12020294
- By:
- Publication type:
- Article
Evaluation of etanercept (a tumor necrosis factor alpha inhibitor) as an effective treatment for joint disease in mucopolysaccharidosis type I. A case report with whole-body magnetic resonance imaging.
- Published in:
- Frontiers in Medicine, 2024, p. 01, doi. 10.3389/fmed.2023.1252704
- By:
- Publication type:
- Article
Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children.
- Published in:
- Children, 2023, v. 10, n. 8, p. 1366, doi. 10.3390/children10081366
- By:
- Publication type:
- Article
Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study.
- Published in:
- Biomedicines, 2023, v. 11, n. 5, p. 1503, doi. 10.3390/biomedicines11051503
- By:
- Publication type:
- Article
COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report.
- Published in:
- Biomedicines, 2023, v. 11, n. 3, p. 870, doi. 10.3390/biomedicines11030870
- By:
- Publication type:
- Article
Comparison of different treatment approaches of pediatric chronic non-bacterial osteomyelitis.
- Published in:
- Rheumatology International, 2019, v. 39, n. 1, p. 89, doi. 10.1007/s00296-018-4151-9
- By:
- Publication type:
- Article
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
- Published in:
- Pediatric Rheumatology, 2015, v. 13, n. 1, p. 1, doi. 10.1186/1546-0096-13-4
- By:
- Publication type:
- Article
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
- Published in:
- Pediatric Rheumatology, 2015, v. 13, n. 1, p. 1, doi. 10.1186/1546-0096-13-4
- By:
- Publication type:
- Article
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
- Published in:
- Pediatric Rheumatology, 2015, v. 13, n. 1, p. 1, doi. 10.1186/1546-0096-13-4
- By:
- Publication type:
- Article
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
- Published in:
- Pediatric Rheumatology, 2015, v. 13, n. 1, p. 1, doi. 10.1186/1546-0096-13-4
- By:
- Publication type:
- Article
A87: Different Tocilizumab Therapeutic Protocols and Possibility Achieving Tocilizumab-Off Remission in Systemic Juvenile Idiopathic Arthritis.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, p. S120, doi. 10.1002/art.38503
- By:
- Publication type:
- Article